SCHEMBL4513056

SCHEMBL4513056

CC(=O)N1CC[C@H](O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL50397 1.00
SCHEMBL524422 1.00
SCHEMBL20738739 0.86 CA12 (0.52)
SCHEMBL3606966 0.86 CA12 (0.52)
SCHEMBL4279033 0.86 CA12 (0.52)
SCHEMBL83783 0.85 CYP1A2 (0.50)
SCHEMBL524200 0.85 CA12 (0.46)
SCHEMBL21023431 0.85 CA12 (0.46)
SCHEMBL16727358 0.80 EPHX2 (0.38)
SCHEMBL22826051 0.80 DPP4 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114585619-B Alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2024-09-27 CN claimed
CN-114585619-A alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2022-06-03 CN claimed
US-20260070888-A1 7-ALKOXYQUINOLINES AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2026-03-12 US disclosed
WO-2025062157-A1 NEW TREATMENTS FOR PAIN SEVENLESS THERAPEUTICS LIMITED (GB) 2025-03-27 WO disclosed
US-20240391875-A1 ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2024-11-28 US disclosed
CN-114585619-B Alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2024-09-27 CN disclosed
WO-2023072974-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-05-04 WO disclosed
WO-2023034344-A1 ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 WO disclosed
CN-115697994-A Fused quinazoline derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-02-03 CN disclosed
WO-2022272248-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-12-29 WO disclosed
WO-2022212296-A1 ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2022-10-06 WO disclosed
US-20080269505-A1 Processes for preparing darifenacin hydrobromide TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS 2008-10-30 US disclosed
US-20080214835-A1 Processes for preparing darifenacin hydrobromide TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS 2008-09-04 US disclosed
US-20080214835-A1 Processes for preparing darifenacin hydrobromide TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS 2008-09-04 US disclosed
US-20080214835-A1 Processes for preparing darifenacin hydrobromide TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS 2008-09-04 US disclosed
EP-1877393-A2 PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE Teva Pharmaceutical Fine Chemicals S.R.L. (IT) 2008-01-16 EP disclosed
US-20070203221-A1 (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-08-30 US disclosed
WO-2007076158-A2 PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-07-05 WO disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed